Virginia’s Onshoring Wave Deepens Into Talent and Process Control
Virginia’s biotech onshoring is evolving from factory builds into a broader push for domestic talent, process control, and lower cross-border risk.
What is this trend?
Virginia’s biotech onshoring is moving beyond plant relocation into control of talent pipelines, process quality, and critical production inputs, making integrated U.S. operating capability a competitive moat.
- Onshoring now includes talent, analytics, and GMP-ready workforce pipelines—not just factories.
- Local control over APIs, drug substance, and complex R&D/testing is becoming the new advantage.
- China-linked export controls and transfer scrutiny are raising the cost of offshore dependence.
- Companies with integrated U.S. capacity can capture more value than those competing on commoditized volume.
- Workforce depth and cleaner IP structures are now part of supply-chain resilience.
What’s the latest?
Virginia’s pharma onshoring total reached about $12.6 billion this week as Eli Lilly, AstraZeneca, and Merck added U.S.
How it developed
- Integrated discovery stacks, domestic IP control, and de-risked assets reshape biotech dealmaking
- Biotech Value Is Shifting to Domestic Capacity and Cleaner IP Control
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
If you operate in this industry
If you sell into this industry
Advice for Small Biotechs on Facility Strategy
Interview with Siobhan Fogarty on building flexible vaccine capacity and tighter IP control via in-house prep.
Life Science Connect · YouTube
Beyond globalisation: How geopolitics is reshaping supply chain strategy - Air Cargo Week
Analysis featuring Wouter Dewulf on geopolitics-driven supply-chain shifts toward domestic capacity and cleaner IP control.
Air Cargo Week · News
Read →